![Jonathan Lim](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Lim
Founder at
BOUNDLESS BIO, INC.
Net worth: 417 M $ as of 2026-05-30
Profile
Jonathan E.
Lim was the founder of Eclipse Therapeutics, Inc. founded in 2011, serving as Chairman & Chief Executive Officer from 2011 to 2012.
Dr. Lim is the founder of Boundless Bio, Inc. founded in 2018, serving as Chairman since 2018.
Dr. Lim is the founder of City Hill Ventures LLC founded in 2010, serving as Venture Partner since 2010.
Dr. Lim was the founder of Bonti, Inc. founded in 2015, serving as Chairman from 2015 to 2018.
Dr. Lim was the founder of Ignyta, Inc. founded in 2011, serving as Chairman, President & Chief Executive Officer from 2013 to 2018.
Dr. Lim is the founder of Ignyta Operating, Inc. founded in 2011, serving as Chairman, President & Chief Executive Officer since 2013.
Dr. Lim is the founder of Erasca, Inc. founded in 2018, serving as Chairman & Chief Executive Officer since 2019.
Dr. Lim is also the founder of Medenovo Management LLC..
Dr. Lim is currently Independent Director at Maze Therapeutics, Inc. since 2019.
Dr. Lim is currently Member-Overseers Board at The Scripps Research Institute since 2018.
Dr. Lim is currently Member-Visitors Board at Moores Cancer Center since 2015.
Dr. Lim is currently Member-Interdisciplinary Biosciences Council at Stanford University since 2014.
Dr. Lim is currently Venture Partner at ARCH Venture Partners LLC since 2018.
Dr. Lim was President, Chief Executive Officer & Director at Halozyme Therapeutics, Inc. from 2005 to 2010.
Dr. Lim was Independent Non-Executive Director at Bionomics Ltd. from 2013 to 2015.
Dr. Lim was Member-Strategic Planning Committee at American Medical Association from 2002 to 2005.
Dr. Lim completed undergraduate and graduate degrees at Stanford University.
Dr. Lim earned a doctorate degree at McGill University.
Dr. Lim completed a graduate degree at Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ERASCA, INC. 10.4% | 2026-04-14 | 32,355,576 ( 10.4% ) | 415 M $ | 2026-05-30 |
BOUNDLESS BIO INC. 2.91% | 2026-06-14 | 653,479 ( 2.91% ) | 947 545 $ | 2026-05-30 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases 0.04% | 2026-06-07 | 20,744 ( 0.04% ) | 548 886 $ | 2026-05-30 |
Jonathan Lim active positions
| Companies | Position | Start |
|---|---|---|
| ERASCA, INC. | Chief Executive Officer | 2019-02-28 |
| BOUNDLESS BIO, INC. | Founder | 2018-04-09 |
Moores Cancer Center | Corporate Officer/Principal | 2014-12-31 |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 2018-09-30 |
ARCH Venture Partners LLC
 ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Private Equity Investor | 2018-11-30 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Director/Board Member | 2019-10-22 |
Ignyta Operating, Inc.
 Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Chief Executive Officer | 2011-07-31 |
City Hill Ventures LLC
 City Hill Ventures LLC Investment ManagersFinance City Hill Ventures invests in companies located in the United States. The firm focuses on biotechnology, clean technology and media & entertainment sectors and industries. It participates in seed, early and later stage capital requirements with an investment size ranging from USD 0.1 to 20 million. It also makes co- investments. | Founder | 2011-04-17 |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 2013-12-31 |
Former positions of Jonathan Lim
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Jonathan Lim
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
55
1st degree connections
18
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 18 |
|---|---|
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
American Medical Association
 American Medical Association Miscellaneous Commercial ServicesCommercial Services Protects the interests of physicians and supports the growth of medical science | Commercial Services |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Finance |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bionomics Ltd.
 Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Health Technology |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eclipse Therapeutics, Inc.
 Eclipse Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics that target cancer stem cells and other forms cancer treatment | Health Technology |
City Hill Ventures LLC
City Hill Ventures LLC Investment ManagersFinance City Hill Ventures invests in companies located in the United States. The firm focuses on biotechnology, clean technology and media & entertainment sectors and industries. It participates in seed, early and later stage capital requirements with an investment size ranging from USD 0.1 to 20 million. It also makes co- investments. | Finance |
Medenovo Management LLC
 Medenovo Management LLC Medical SpecialtiesHealth Technology Develops medical devices | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Bonti, Inc.
 Bonti, Inc. Pharmaceuticals: MajorHealth Technology Develops novel treatments | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Boundless Bio, Inc.
 Boundless Bio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that develops cancer therapeutics | Health Technology |
Moores Cancer Center |
- Stock Market
- Insiders
- Jonathan Lim
